The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
A PD-1/VEGF bispecific antibody is a type of cancer drug designed to target both the programmed cell death protein 1, or PD-1, on immune cells and vascular endothelial growth factor, or VEGF, on tumor ...
Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected ...
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...
Summit Therapeutics and its Chinese partner Akeso have a few competitors now.
(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...
As the 11th Merck Foundation Africa Asia Luminary opens in Tanzania, stakeholders have emphasised the crucial role of healthcare in driving economic and social progress. They spoke at the opening ...
Pakistan has been elected to preside over the 63rd session of the United Nations Commission on Narcotic Drugs in 2020. Earlier, in May, 2019, Pakistan was elected as Member of the Commission for a ...
The 11th Edition of Merck Foundation Africa Asia Luminary was officially inaugurated by The President of the United Republic of Tanzania, H.E. Dr. SAMIA SULUHU HASSAN, Chairman of Merck Foundation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback